ReviewFrontiers in immunology2018
The Inflammatory Response to Ventricular Assist Devices.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Preliminary report of extracorporeal blood purification therapy in patients receiving LVAD: Cytosorb or Jafron HA330.The journal of extra-corporeal technology · 2024Trial
- Incidence, Predictors and Outcome of Vasoplegia After Left Ventricular Assist Device Implantation.Journal of cardiovascular development and disease · 2026Article
- Implantation of a Continuous-Flow Left Ventricular Assist Device During Cardiopulmonary Bypass Is Associated with a Significant and Transient Acute Thromboinflammatory Response.International journal of molecular sciences · 2026Article
- Extracorporeal Cytokine Adsorption in Acute Cardiovascular Care: Pathophysiological Insights and Clinical Perspectives.Biomedicines · 2026Review
- Role for inflammatory markers in predicting right ventricular failure in mechanical assist device recipients.ESC heart failure · 2025Review
- Induction therapy confers survival advantage in mechanically supported patients regardless of peak CPRA in heart transplantation.JHLT open · 2025Article
- Implications of Preoperative C-Reactive Protein Levels in Heart Transplant Patients-A Single-Center Retrospective Study.Journal of clinical medicine · 2024Article
- Biosensors with left ventricular assist devices.Heart failure reviews · 2024Review
- Iron Deficiency in Patients with Left Ventricular Assist Devices.Cardiac failure review · 2024Review
- Interplay between driveline infection, vessel wall inflammation, cerebrovascular events and mortality in patients with left ventricular assist device.Scientific reports · 2023Article
- Body mass index-dependent immunological profile changes after left ventricular assist device implantation.Frontiers in immunology · 2023Article
- Advanced strategies to thwart foreign body response to implantable devices.Bioengineering & translational medicine · 2022Review
- Neutrophil dysfunction due to continuous mechanical shear exposure in mechanically assisted circulation in vitro.Artificial organs · 2022Article
- The Role of Endothelium in COVID-19.International journal of molecular sciences · 2021Review
- In-depth review of cardiopulmonary support in COVID-19 patients with heart failure.World journal of cardiology · 2021Review
- Factors associated with neutropenia post heart transplantation.Transplant infectious disease : an official journal of the Transplantation Society · 2021Article
- Heart failure and COVID-19.Heart failure reviews · 2021Review
- The Degree of Cardiac Remodelling before Overload Relief Triggers Different Transcriptome and miRome Signatures during Reverse Remodelling (RR)-Molecular Signature Differ with the Extent of RR.International journal of molecular sciences · 2020Article
- Gastrointestinal Bleeding as a Complication in Continuous Flow Ventricular Assist Devices: A Systematic Review With Meta-Analysis.Journal of clinical medicine research · 2020Article
- Considerations for Heart Failure Care During the COVID-19 Pandemic.JACC. Heart failure · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complications include infection and thrombosis which share underpinning contribution from the inflammatory response and remain common risks from VAD implantation. An added and underappreciated difficulty in designing a VAD that supports heart function and aids the repair of damaged myocardium is that different types of HF are accompanied by different inflammatory profiles that can affect the response to the implanted device. Circulating inflammatory markers and changes in leukocyte phenotypes receive much attention as biomarkers for mortality and disease progression. However, they are seldom used to monitor progress during and outcomes from VAD therapy or during the design phase for new devices. Even the partial reversal of heart damage associated with heart failure is a desirable outcome from VAD use. Therefore, improved understanding of the interplay between VADs and the recipient's inflammatory response would potentially increase their uptake, improve patient lives, and fuel research related to other blood-contacting medical devices. Here we provide a review of what is currently known about inflammation in heart failure and how this inflammatory profile is altered in heart failure patients receiving VAD therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.